glp 1 and osteoporosis Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity | International GLP-1 weight loss drug study

TLDR...I made it one month (barely)

Lets separate guesses from facts.

Novo Nordisk is seeking to replace the existing glucagon-like peptide-1 (GLP-1) receptor agonist (RA) with a second-generation drug, semaglutide, to fight diabetes and obesity in Korea.On Thursday, the Ministry of Food and Drug Safety authorized the use of Novo Nordisks Ozempic to treat adults with

This state-of-the-art review explores the relationship between depression and diabetes, highlighting the two-way influences that make treatment challenging and worsen the outcomes of both conditions

Arizona OPEN ACCESS PUBLISHED:30 October 2024 CITATION:Chakkera, S

Cleavage of albumin by carboxypeptidase A in vivo reduces its binding to FcRn and plasma half-life